Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
ABSK-121 by Abbisko Therapeutics for Solid Tumor: Likelihood of Approval
ABSK-121 is under clinical development by Abbisko Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
ABSK-112 by Abbisko Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
ABSK-112 is under clinical development by Abbisko Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to...
ABSK-043 by Abbisko Therapeutics for Solid Tumor: Likelihood of Approval
ABSK-043 is under clinical development by Abbisko Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
ABSK-043 by Abbisko Therapeutics for Melanoma: Likelihood of Approval
ABSK-043 is under clinical development by Abbisko Therapeutics and currently in Phase I for Melanoma. According to GlobalData, Phase I...
Pimicotinib hydrochloride by Abbisko Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
Pimicotinib hydrochloride is under clinical development by Abbisko Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According...
Pimicotinib hydrochloride by Abbisko Therapeutics for Pancreatic Cancer: Likelihood of Approval
Pimicotinib hydrochloride is under clinical development by Abbisko Therapeutics and currently in Phase I for Pancreatic Cancer. According to GlobalData,...
Pimicotinib hydrochloride by Abbisko Therapeutics for Solid Tumor: Likelihood of Approval
Pimicotinib hydrochloride is under clinical development by Abbisko Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData,...
Pimicotinib hydrochloride by Abbisko Therapeutics for Small-Cell Lung Cancer: Likelihood of Approval
Pimicotinib hydrochloride is under clinical development by Abbisko Therapeutics and currently in Phase I for Small-Cell Lung Cancer. According to...
ABSK-043 by Abbisko Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
ABSK-043 is under clinical development by Abbisko Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Pimicotinib by Abbisko Therapeutics for Pancreatic Cancer: Likelihood of Approval
Pimicotinib is under clinical development by Abbisko Therapeutics and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase...
Pimicotinib by Abbisko Therapeutics for Tenosynovial Giant Cell Tumor: Likelihood of Approval
Pimicotinib is under clinical development by Abbisko Therapeutics and currently in Phase III for Tenosynovial Giant Cell Tumor. According to...
Pimicotinib by Abbisko Therapeutics for Solid Tumor: Likelihood of Approval
Pimicotinib is under clinical development by Abbisko Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Pimicotinib by Abbisko Therapeutics for Small-Cell Lung Cancer: Likelihood of Approval
Pimicotinib is under clinical development by Abbisko Therapeutics and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData,...
Pimicotinib by Abbisko Therapeutics for Advanced Malignancy: Likelihood of Approval
Pimicotinib is under clinical development by Abbisko Therapeutics and currently in Phase I for Advanced Malignancy. According to GlobalData, Phase...